CURE bleeding criteria: Difference between revisions
m (Bot: Removing from Primary care) |
|||
Line 19: | Line 19: | ||
== References == | == References == | ||
{{Reflist}} | {{Reflist}} | ||
{{WH}} | |||
{{WS}} | |||
[[Category:Medical emergencies]] | [[Category:Medical emergencies]] | ||
[[Category:Blood]] | [[Category:Blood]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Needs overview]] | [[Category:Needs overview]] | ||
Latest revision as of 21:11, 29 July 2020
Bleeding Microchapters |
Treatment |
---|
Reversal of Anticoagulation and Antiplatelet in Active Bleed |
Perioperative Bleeding |
CURE bleeding criteria On the Web |
American Roentgen Ray Society Images of CURE bleeding criteria |
Risk calculators and risk factors for CURE bleeding criteria |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
CURE Clinical Trials:
The Clopidogrel In Unstable Angina To Prevent Recurrent Events Trial
Clopidogrel In Unstable Angina To Prevent Recurrent Ischemic Events[1]
“ |
Life-threatening (fatal, intracranial, requiring surgical intervention, results in substantial hypotension requiring the use of intravenous inotropic agents) Hemoglobin decrease ≥5 g/dL or required ≥4 U of blood Other major bleeding Transfusion of 2–3 U, intraocular
Led to discontinuation of study drug |
” |
References
- ↑ Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S (2006). "Adverse impact of bleeding on prognosis in patients with acute coronary syndromes". Circulation. 114 (8): 774–82. doi:10.1161/CIRCULATIONAHA.106.612812. PMID 16908769.